title: Lipiodol retention and massive necrosis after lipiodol-chemoembolization of hepatocellular carcinoma: correlation between computed tomography and histopathology.
abstract: This retrospective study examined the computed tomography (CT) criteria for judging the effectiveness of transcatheter arterial Lipiodol-chemoembolization (Lp-chemo-TAE) in 35 cases with hepatocellular carcinoma (HCC). Massive necrosis, defined as involving 97% or more of the HCC nodule, was observed in 15 cases after Lp-chemo-TAE, whereas nonmassive necrosis, defined as involving < or = 96% of the HCC nodule, was observed in the remaining 20 cases. In 12 of 15 cases (80%) with massive necrosis, uniform dense retention of Lipiodol (Lp) was observed throughout the HCC nodule on CT images 3-4 weeks after Lp-chemo-TAE as opposed to only one (5%) of 20 cases with nonmassive necrosis (p < 0.01). Eight of nine cases (89%) with massive necrosis had tumor attenuation values of 365 Hounsfield units (HU) or greater on CT images 3-4 weeks after embolization, as opposed to only four (27%) of 15 cases with nonmassive necrosis (p < 0.01). We conclude that the effectiveness of the Lp-chemo-TAE can be judged on CT from the degree and duration of Lp retention in the HCC nodule and the measurement of the attenuation value of the HCC nodule.
authors.affiliation: Department of Radiology, Gifu University School of Medicine, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Imaeda
authors.forename: Y
authors.initials: Y
authors.lastname: Yamawaki
authors.forename: M
authors.initials: M
authors.lastname: Seki
authors.forename: H
authors.initials: H
authors.lastname: Goto
authors.forename: G
authors.initials: G
authors.lastname: Iinuma
authors.forename: M
authors.initials: M
authors.lastname: Kanematsu
authors.forename: R
authors.initials: R
authors.lastname: Mochizuki
authors.forename: H
authors.initials: H
authors.lastname: Doi
authors.forename: S
authors.initials: S
authors.lastname: Saji
authors.forename: K
authors.initials: K
authors.lastname: Shimokawa
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007459:Iodized Oil / Q000008:administration & dosage*; D008099:Liver / Q000000981:diagnostic imaging* / Q000473:pathology; D008113:Liver Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D009336:Necrosis; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed
chemical_list: D015251:Epirubicin; D016685:Mitomycin; D007459:Iodized Oil